331 related articles for article (PubMed ID: 12941478)
1. Interleukin-4 directly inhibits tumor necrosis factor-alpha-mediated osteoclast formation in mouse bone marrow macrophages.
Kitaura H; Nagata N; Fujimura Y; Hotokezaka H; Tatamiya M; Nakao N; Yoshida N; Nakayama K
Immunol Lett; 2003 Sep; 88(3):193-8. PubMed ID: 12941478
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
Nagata N; Kitaura H; Yoshida N; Nakayama K
Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
[TBL] [Abstract][Full Text] [Related]
4. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
5. CpG oligonucleotides: novel regulators of osteoclast differentiation.
Zou W; Schwartz H; Endres S; Hartmann G; Bar-Shavit Z
FASEB J; 2002 Mar; 16(3):274-82. PubMed ID: 11874977
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway.
Palmqvist P; Lundberg P; Persson E; Johansson A; Lundgren I; Lie A; Conaway HH; Lerner UH
J Biol Chem; 2006 Feb; 281(5):2414-29. PubMed ID: 16251181
[TBL] [Abstract][Full Text] [Related]
7. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling.
Rahman MM; Bhattacharya A; Fernandes G
J Lipid Res; 2006 Aug; 47(8):1739-48. PubMed ID: 16702601
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.
Kimachi K; Kajiya H; Nakayama S; Ikebe T; Okabe K
Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):297-308. PubMed ID: 21225243
[TBL] [Abstract][Full Text] [Related]
9. Primary human bone marrow adipocytes support TNF-α-induced osteoclast differentiation and function through RANKL expression.
Goto H; Hozumi A; Osaki M; Fukushima T; Sakamoto K; Yonekura A; Tomita M; Furukawa K; Shindo H; Baba H
Cytokine; 2011 Dec; 56(3):662-8. PubMed ID: 21963155
[TBL] [Abstract][Full Text] [Related]
10. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
11. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage.
Khapli SM; Mangashetti LS; Yogesha SD; Wani MR
J Immunol; 2003 Jul; 171(1):142-51. PubMed ID: 12816992
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism.
Zou W; Hakim I; Tschoep K; Endres S; Bar-Shavit Z
J Cell Biochem; 2001 Jun 26-Jul 25; 83(1):70-83. PubMed ID: 11500955
[TBL] [Abstract][Full Text] [Related]
13. The generation of highly enriched osteoclast-lineage cell populations.
Quinn JM; Whitty GA; Byrne RJ; Gillespie MT; Hamilton JA
Bone; 2002 Jan; 30(1):164-70. PubMed ID: 11792580
[TBL] [Abstract][Full Text] [Related]
14. A rapid multiparameter approach to study factors that regulate osteoclastogenesis: demonstration of the combinatorial dominant effects of TNF-alpha and TGF-ss in RANKL-mediated osteoclastogenesis.
Huang W; Drissi MH; O'Keefe RJ; Schwarz EM
Calcif Tissue Int; 2003 Dec; 73(6):584-93. PubMed ID: 14517717
[TBL] [Abstract][Full Text] [Related]
15. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
Gong W; Dou H; Liu X; Sun L; Hou Y
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
[TBL] [Abstract][Full Text] [Related]
16. Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides.
Amcheslavsky A; Bar-Shavit Z
J Cell Physiol; 2006 Apr; 207(1):244-50. PubMed ID: 16402377
[TBL] [Abstract][Full Text] [Related]
17. [Effects of paeonol on the function of bone marrow-derived macrophage from Porphyromonas gingivalis-induced mice].
Zhu C; Lingkai S
Hua Xi Kou Qiang Yi Xue Za Zhi; 2017 Apr; 35(2):139-144. PubMed ID: 28682542
[TBL] [Abstract][Full Text] [Related]
18. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells.
Yang CR; Wang JH; Hsieh SL; Wang SM; Hsu TL; Lin WW
Cell Death Differ; 2004 Jul; 11 Suppl 1():S97-107. PubMed ID: 15002040
[TBL] [Abstract][Full Text] [Related]
19. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
Sankar U; Patel K; Rosol TJ; Ostrowski MC
J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
[TBL] [Abstract][Full Text] [Related]
20. IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL.
Moreno JL; Kaczmarek M; Keegan AD; Tondravi M
Blood; 2003 Aug; 102(3):1078-86. PubMed ID: 12689929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
